Compugen (NASDAQ:CGEN – Get Free Report) and OKYO Pharma (NASDAQ:OKYO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability.
Insider and Institutional Ownership
12.2% of Compugen shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Compugen has a beta of 2.79, suggesting that its stock price is 179% more volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Compugen | 1 | 0 | 2 | 1 | 2.75 |
| OKYO Pharma | 1 | 1 | 3 | 0 | 2.40 |
Compugen presently has a consensus price target of $5.00, suggesting a potential upside of 74.83%. OKYO Pharma has a consensus price target of $6.33, suggesting a potential upside of 298.32%. Given OKYO Pharma’s higher possible upside, analysts plainly believe OKYO Pharma is more favorable than Compugen.
Profitability
This table compares Compugen and OKYO Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Compugen | 48.57% | 55.68% | 29.68% |
| OKYO Pharma | N/A | N/A | N/A |
Earnings & Valuation
This table compares Compugen and OKYO Pharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Compugen | $72.76 million | 3.72 | $35.34 million | $0.37 | 7.73 |
| OKYO Pharma | N/A | N/A | -$4.71 million | N/A | N/A |
Compugen has higher revenue and earnings than OKYO Pharma.
Summary
Compugen beats OKYO Pharma on 9 of the 12 factors compared between the two stocks.
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
About OKYO Pharma
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
